Loading...
Hospitalized patients with COVID-19 have substantial risk for thrombosis. In previous studies, researchers have examined the optimal level of anticoagulation to prevent thrombosis without incurring excess bleeding risk in hospitalized and critically ill patients. Guidelines largely recommend prophylactic dosing (e.g., 40-mg enoxaparin) for patients in intensive care and therapeutic dosing for those on the wards (Blood Adv 2021; 5:3951 and NIH COVID-19 Treatment Guidelines: Antithrombotic Therapy).
In this open-label, randomized, multicenter trial of 334 patients in France, researchers evaluated all-cause mortality and time to clinical improvement in patients admitted for COVID-19–related pneumonia and hypoxemia. Almost all patients (90%) wer…